Merck Stock Edges Higher on FDA Vaccine Approval

The U.S. Food and Drug Administration (FDA) approved Merck & Co Inc's (NYSE:MRK) next-generation vaccine to protect adults against the pneumococcal disease. The company said the vaccine could become available later this summer, pending recommendation from the Centers for Disease Control and Prevention (CDC). In response, MRK is up 0.3% to trade at $127.90 at last check.Over the last few months, the security has repeatedly attempted to conquer its March 27, record high of $133.08, but the $130 level keeps ac ...